跳至主要内容
临床试验/IRCT20190706044111N25
IRCT20190706044111N25已完成未知

A randomized, open label, single dose, crossover, bioequivalence study of Fexofenadine 120mg tablet of Jaber Ebne Hayyan Pharm. Co., IRAN in comparison of Telfast 120mg tablet of Sanofi in 24 healthy adult subjects under fasting condition

Jaber Ebne Hayyan Pharm. Co..0 个研究点目标入组 48 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
48

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 50 years(—)
性别
All

入选标准

  • Aged between 18 - 50 years
  • - Body weight between 50 – 100 kg
  • - Having good health on the basis of medical history and physical & clinical examination
  • - Understand the procedures and give written informed consent

排除标准

  • Subject had undergone surgery of the gastro-intestinal tract treatment.
  • Subject had donated a unit of blood or participated in another clinical trial, within the last two months before the first
  • Subject had a history of drug or alcohol abuse.
  • Subject who smokes more than 10 cigarettes per day.
  • Subject had used any prescription medication within 14 days, or any non-prescription medication within 7 days, before the first treatment.

研究者

发起方
Jaber Ebne Hayyan Pharm. Co..

相似试验

Bioequivalence study of Fexofenadine 120mg tablet of... | 临床试验